Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.
Alsiö Å, Rembeck K, Askarieh G, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Nasic S, Westin J, Hellstrand K, Norkrans G, Lagging M. Alsiö Å, et al. Among authors: rembeck k. PLoS One. 2012;7(5):e37521. doi: 10.1371/journal.pone.0037521. Epub 2012 May 24. PLoS One. 2012. PMID: 22655053 Free PMC article. Clinical Trial.
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection.
Rembeck K, Maglio C, Lagging M, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Norkrans G, Hellstrand K, Lindh M, Pirazzi C, Burza MA, Romeo S, Westin J; NORDynamIC group. Rembeck K, et al. BMC Med Genet. 2012 Sep 14;13:82. doi: 10.1186/1471-2350-13-82. BMC Med Genet. 2012. PMID: 22978414 Free PMC article. Clinical Trial.
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.
Rembeck K, Waldenström J, Hellstrand K, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Lagging M. Rembeck K, et al. Hepatology. 2014 Jun;59(6):2131-9. doi: 10.1002/hep.27009. Epub 2014 Apr 25. Hepatology. 2014. PMID: 24519039 Clinical Trial.
Reply: To PMID 24519039.
Lagging M, Rembeck K, Waldenström J, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Hellstrand K. Lagging M, et al. Among authors: rembeck k. Hepatology. 2014 Dec;60(6):2130-1. doi: 10.1002/hep.27108. Epub 2014 Sep 24. Hepatology. 2014. PMID: 24591101 No abstract available.
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.
Waldenström J, Färkkilä M, Rembeck K, Norkrans G, Langeland N, Mørch K, Pedersen C, Rauning Buhl M, Nieminen U, Nuutinen H, Alsiö Å, Holmström L, Jungnelius R, Lund K, Rubensson A, Torell E, Westin J, Lagging M. Waldenström J, et al. Among authors: rembeck k. Scand J Gastroenterol. 2016 Mar;51(3):337-43. doi: 10.3109/00365521.2015.1087588. Epub 2015 Sep 29. Scand J Gastroenterol. 2016. PMID: 26418670 Free PMC article. Clinical Trial.
17 results